Geminor MP 2 Tablet SR is a combination oral antidiabetic medication containing Glimepiride 2 mg, Metformin 500 mg, and Pioglitazone 15 mg, formulated to improve glycemic control in patients with type 2 diabetes mellitus. Glimepiride, a sulfonylurea class agent, stimulates pancreatic beta cells to increase insulin secretion, thereby reducing blood glucose levels. Metformin, a biguanide, primarily decreases hepatic glucose production and enhances peripheral insulin sensitivity, contributing to improved glucose uptake and utilization. Pioglitazone, a thiazolidinedione, acts as an insulin sensitizer by activating peroxisome proliferator-activated receptor gamma (PPAR-γ), which regulates the transcription of insulin-responsive genes involved in glucose and lipid metabolism. The sustained-release formulation ensures a gradual release of active ingredients, promoting better patient compliance and stable plasma drug concentrations. Geminor MP 2 Tablet SR is indicated for adults inadequately controlled on diet and exercise alone or on monotherapy, providing a multifaceted approach to managing hyperglycemia through complementary mechanisms. It is essential to monitor renal and hepatic function periodically during therapy and to be vigilant for potential adverse effects such as hypoglycemia, gastrointestinal disturbances, weight gain, and fluid retention. This combination therapy should be used under medical supervision with appropriate lifestyle modifications for optimal diabetes management.